What Is PMOS? Everything You Need to Know About the Reason Behind The Renaming Of PCOS
For 170 million women of reproductive age worldwide, the condition long known as PCOS just got a new name — and the change carries real stakes for diagnosis, stigma and care. After 14 years of work, polycystic ovary syndrome has been officially renamed Polyendocrine Metabolic Ovarian Syndrome, or PMOS, in a global consensus process that researchers describe as the largest medical name change in history.
The shift, led by Professor Helena Teede of Monash University’s Monash Centre for Health Research & Implementation, aims to fix a label that doctors and patients say has obscured the condition’s true scope for decades. Up to 70% of affected people currently go undiagnosed.
Why the PCOS Name Change Happened
The original name was misleading. Despite the word “polycystic,” many patients with the condition do not actually have ovarian cysts — and the cysts that do appear are not pathological.
“What we now know is that there is actually no increase in abnormal cysts on the ovary, and the diverse features of the condition were often unappreciated,” Teede said. “It was heart-breaking to see the delayed diagnosis, limited awareness and inadequate care afforded those affected by this neglected condition.”
The renaming process drew on feedback from more than 14,000 patients and health professionals across 56 medical, scientific and patient advocacy organizations.
What PMOS Means and How It’s Diagnosed
PMOS is a hormonal imbalance in which the ovaries produce unusually high levels of androgens, throwing off reproductive hormones. The result is irregular menstrual cycles, missed periods and unpredictable ovulation, according to the Cleveland Clinic. Small follicle cysts may appear on ultrasound — but they are not required for diagnosis.
For adults 20 and older, diagnosis requires at least two of three criteria:
- Irregular or absent ovulation
- Elevated androgen levels or symptoms of excess androgens
- Polycystic ovaries on ultrasound or elevated anti-Müllerian hormone levels
For adolescents ages 10 to 19, both irregular ovulation and hyperandrogenism are required. Diagnosis only happens after ruling out other disorders.
Why This Is More Than a Rebrand for Polycystic Ovary Syndrome Patients
The new name reflects a shift in how researchers understand the condition. Newer evidence shows PMOS is driven by broader endocrine dysfunction involving insulin, androgens, neuroendocrine hormones and ovarian hormones — not a gynecological problem alone.
Symptoms can stretch across multiple body systems:
- Metabolic: obesity, insulin resistance, type 2 diabetes, high blood pressure, abnormal cholesterol, fatty liver disease, cardiovascular disease and sleep apnea
- Reproductive: irregular cycles, infertility, pregnancy complications and increased endometrial cancer risk
- Psychological: depression, anxiety, eating disorders and reduced quality of life
- Dermatological: acne, hair thinning and excess facial or body hair
Patients often have a higher average BMI, which can worsen symptom severity. Researchers describe it as a multisystem disorder with long-term health and economic consequences.
A multiyear transition plan will update medical guidelines, education materials and international disease classification systems.
This article was created by content specialists using various tools, including AI.
